Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

National Institute for Health and Care Excellence NICE logo

NICE backtracks on prostate cancer drug enzalutamide

Says Astellas and Medivation's Xtandi can be used within the NHS in England and Wales

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

National Institute for Health and Care Excellence NICE logo

NICE backs two cancer drugs

Boehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use

National Institute for Health and Care Excellence NICE logo

NICE gives partial backing to Ferring’s prostate cancer drug

Firmagon on course for use on NHS in England and Wales

Roche - Basel

NICE reverses decision to restrict Tarceva access

Roche says “voices of clinicians and patients have been heard”

National Institute for Health and Care Excellence NICE logo

Final NICE ‘no’ for J&J’s Stelara in psoriatic arthritis

Committee says drug is more expensive and less effective than TNF alpha inhibitors

National Institute for Health and Care Excellence NICE logo

NICE consults on value-based assessment changes

Aims to create a more flexible approach to drug funding decisions for NHS in England and Wales

- PMLiVE

Final NICE backing for MabThera in rare condition

Roche drug available in England and Wales to treat rare form of vasculitis

- PMLiVE

NICE refuses to back Zaltrap as Sanofi exhausts its options

Patient access scheme and appeal fail to overcome cost concerns

National Institute for Health and Care Excellence NICE logo

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

National Institute for Health and Care Excellence NICE logo

NICE denies pharma influence on statin guidance

Responds to accusations committee members were ‘in the pay’ of drug firms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links